Key Takeaways
- RapidPulse secured a $48 million oversubscribed Series B round co‑led by Medtronic, TechWald Next and S3 Ventures, with participation from SBI Investment Company, the Florida Opportunity Fund and existing backers Santé Ventures, Syntheon, Hatteras Venture Partners and Epidarex Capital.
- The proceeds will fund completion of the TURBO IDE study, broaden clinical exposure at leading stroke centers, and advance the company’s aspiration‑based thrombectomy platform toward a potential FDA submission.
- RapidPulse’s technology employs a controlled cyclic (pulsed) aspiration method designed to improve clot engagement, removal efficiency and procedural consistency during mechanical thrombectomy for acute ischemic stroke.
- The TURBO study (Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions) is underway in the United States and Europe and aims to generate the data needed for U.S. regulatory clearance.
- Strategic investors such as Medtronic bring not only capital but also commercial expertise and validation of the clinical need for improved stroke reperfusion therapies.
- RapidPulse was spun out of Syntheon, a medical‑device incubator with a track record of over 50 million patients treated and $6 billion in revenue generated for partner companies.
- Leadership emphasizes that the financing reflects growing confidence in the differentiated technology, strong IP portfolio and experienced team needed to bring a new option to neurointerventional physicians.
- If clinical data remain supportive, RapidPulse plans to seek FDA approval and expand its catheter portfolio to treat a wider range of vessel sizes and clot locations.
Overview of the Series B Financing
RapidPulse announced that it has closed a $48 million Series B financing round that was substantially oversubscribed. The round was co‑led by three prominent investors: Medtronic, a global leader in medical technology; TechWald Next, which focuses on emerging cardiovascular and neurovascular innovations; and S3 Ventures, a venture firm managing over $1.2 billion across healthcare, business technology and consumer digital sectors. Additional participation came from SBI Investment Company, the Florida Opportunity Fund, and existing shareholders Santé Ventures, Syntheon, Hatteras Venture Partners and Epidarex Capital. The broad and high‑caliber syndicate underscores strong confidence in RapidPulse’s mission to improve outcomes for patients suffering acute ischemic stroke.
Allocation of the New Capital
The company intends to deploy the fresh capital primarily to complete the TURBO Investigational Device Exemption (IDE) study, which is evaluating its pulsed‑aspiration thrombectomy system in the United States and Europe. Funds will also support expanding clinical experience with the system at leading stroke centers, thereby generating real‑world performance data across diverse patient populations, clot compositions and practice settings. In parallel, RapidPulse will continue advancing its proprietary technology platform, including refinements to the catheter designs and aspiration console. Should the clinical data warrant, the financing positions the company to pursue a U.S. Food and Drug Administration (FDA) submission for market clearance.
RapidPulse’s Aspiration Technology for Stroke
At the core of RapidPulse’s platform is an aspiration‑based thrombectomy system that uses a controlled cyclic suction approach rather than relying solely on continuous vacuum. By delivering pulsatile suction cycles, the technology aims to enhance clot engagement, improve the efficiency of clot capture and retrieval, and increase procedural consistency—factors that are critical when treating the varied clot architectures encountered in ischemic stroke. The system comprises a range of catheter diameters and lengths intended to accommodate different intracranial vessel sizes and clot locations, from the proximal internal carotid artery to more distal middle cerebral artery branches. This modularity is designed to give neurointerventionalists flexibility while maintaining a consistent mechanism of action.
Mechanical Thrombectomy and the Need for Improved Clot Removal
Acute ischemic stroke results from a thrombus obstructing cerebral arterial flow, leading to rapid neuronal injury if perfusion is not restored promptly. Mechanical thrombectomy is the current standard of care for large‑vessel occlusions, involving the navigation of a catheter to the clot site and its physical removal. While effective, outcomes can be limited by clot composition, adhesion to the vessel wall, and the efficiency of the retrieval device. Aspiration techniques address some of these challenges by directly drawing the clot into the catheter, but conventional continuous suction can sometimes fail to engage loosely packed or friable clots. RapidPulse’s pulsed aspiration seeks to overcome these limitations by creating intermittent pressure gradients that may better “grab” and retain the clot during extraction.
The TURBO Investigational Device Exemption Study
The TURBO study (Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions) is an IDE trial designed to generate the safety and efficacy data necessary for a potential FDA approval pathway. Conducted at selected stroke centers in the United States and Europe, the study enrolls patients with acute ischemic stroke who are eligible for mechanical thrombectomy. Primary endpoints focus on reperfusion success rates, procedural time, and safety metrics such as vessel injury or distal embolization. By completing patient enrollment and follow‑up assessments, RapidPulse aims to demonstrate that its pulsed‑aspiration system achieves non‑inferior or superior reperfusion compared with existing devices, while offering advantages in ease of use and consistency across operators. The Series B financing is earmarked to cover the remaining costs of enrollment, site activation, data monitoring, and statistical analysis for this pivotal trial.
Strategic Value of Investor Participation
The inclusion of Medtronic as a co‑lead investor brings more than capital; it provides strategic alignment with a company that possesses extensive neurovascular product lines, global distribution channels, and deep regulatory expertise. Medtronic’s endorsement signals industry recognition of the clinical need for improved aspiration‑based thrombectomy solutions. TechWald Next’s focus on cardiovascular and neurovascular innovation adds a venture perspective attuned to the nuances of early‑stage medical‑device development, while S3 Ventures’ broad healthcare technology experience offers operational guidance and access to follow‑on funding networks. Together, these investors reinforce the thesis that RapidPulse’s differentiated technology, protected by a growing intellectual‑property portfolio, could become a meaningful alternative for physicians seeking reliable clot removal tools.
Company Heritage and Syntheon Connection
RapidPulse traces its origins to Syntheon, a medical‑device incubator renowned for transforming early concepts into commercially viable products. Syntheon’s portfolio has contributed to therapies that have treated more than 50 million patients and generated over $6 billion in revenue for partner companies. By leveraging Syntheon’s established infrastructure—including regulatory affairs, manufacturing know‑how, and product‑development expertise—RapidPulse is able to accelerate its platform maturation while mitigating some of the typical risks associated with de‑novo device startups. This heritage provides a solid foundation for the company’s ambitions to navigate the complex path from clinical investigation to market approval and eventual commercial launch.
Leadership Perspectives and Future Outlook
Sean McBrayer, Chief Executive Officer of RapidPulse, highlighted that the financing enables the completion of the TURBO study, expansion of clinical experience across top stroke centers, and—contingent on data—a potential FDA submission. He emphasized that the backing from both leading financial investors and a strategic titan like Medtronic reflects growing acknowledgment of the potential impact of their pulsed‑aspiration approach. Alessandro Piga, CEO of TechWald Next, praised RapidPulse as one of the most compelling innovation opportunities in stroke, citing its differentiated technology, strong IP, and seasoned leadership team. Brian R. Smith, Founder and Managing Director of S3 Ventures, noted that the company exemplifies the type of high‑differentiation, rigorously clinically‑validated venture that S3 seeks to support, expressing confidence that the pulsed aspiration technology could meaningfully improve patient outcomes in a disease area with significant unmet need. Collectively, these statements reinforce a shared belief that RapidPulse is well‑positioned to advance its aspiration platform through pivotal trials, regulatory review, and ultimately into widespread clinical use for acute ischemic stroke treatment.